Browse the evidence

Prebiotics can confer health benefits at extraintestinal sites (e.g., skin, vagina, brain) through indirect mechanisms mediated by gut microbiota changes.

Prebiotics can help conditions outside the gut, like skin health or mood, by changing the gut bacteria which then send signals to other parts of the body.

Aspirin should be used infrequently in the routine primary prevention of atherosclerotic cardiovascular disease (ASCVD) because of lack of net benefit.

Do not start taking daily aspirin for heart disease prevention without discussing it with your doctor. For most people in primary prevention, the risk of bleeding outweighs the benefits. Focus on lifestyle changes like diet and exercise instead.

Gut microbiota composition is not a single optimal state but a personalized ecosystem shaped by early-life factors (birth mode, feeding), age, and ongoing lifestyle variables (diet, exercise, BMI), where health is defined by functional balance rather than specific taxonomic abundance.

Do not chase a single 'ideal' bacterial profile. Focus on maintaining a diverse, balanced microbiome through personalized lifestyle choices: prioritize fiber-rich plant foods, regular exercise, and minimizing unnecessary antibiotic use. Recognize that your gut health is shaped by your unique history (birth, early diet) and current habits.

Insulin resistance directly causes cardiovascular disease through three primary mechanisms: signal transduction alteration, impaired substrate metabolism regulation, and altered substrate delivery to the myocardium.

If you have insulin resistance (often associated with obesity or type 2 diabetes), you are at higher risk for heart disease regardless of your cholesterol levels. Addressing insulin sensitivity through lifestyle changes is critical for heart health.

Insulin resistance leads to endothelial dysfunction by selectively impairing nitric oxide (NO) production while activating pro-inflammatory and pro-thrombotic pathways, contributing to hypertension and atherosclerosis.

Insulin resistance damages the lining of your blood vessels (endothelium) by reducing nitric oxide production. This leads to higher blood pressure and increased risk of heart disease. Improving insulin sensitivity helps protect your blood vessels.

Cardiovascular disease (CVD) affects approximately 32.2% of adults with Type 2 Diabetes Mellitus (T2DM) globally, with coronary artery disease (21.2%) and atherosclerosis (29.1%) being the most prevalent comorbidities, while stroke is the least prevalent (7.6%).

If you have Type 2 Diabetes, your risk of cardiovascular disease is significantly higher than the general population, affecting roughly 1 in 3 people in this group. The most common heart issues are coronary artery disease and atherosclerosis. To mitigate this, focus on a comprehensive strategy: control blood sugar, quit smoking, manage blood pressure, treat cholesterol, and maintain a healthy weight. This is not just about sugar; it is about overall heart health.

Cardiovascular disease is the primary cause of mortality in Type 2 Diabetes, accounting for approximately 50.3% of all deaths in this population, with coronary artery disease and stroke being the major contributors.

For people with Type 2 Diabetes, heart disease is not just a complication; it is the leading cause of death, responsible for half of all fatalities. Preventing heart disease is the most critical step for extending life expectancy. This involves aggressive management of blood pressure, cholesterol, and blood sugar, alongside lifestyle changes like smoking cessation and exercise.

Butyrate maintains anaerobic conditions in the colon by activating PPARγ and repressing inducible nitric oxide synthase (iNOS), which prevents the proliferation of pathogenic facultative anaerobes like Enterobacteriaceae.

Maintain a healthy gut barrier by ensuring adequate butyrate production. Butyrate, a short-chain fatty acid produced by bacteria from fiber, activates PPARγ in colon cells to limit oxygen diffusion and repress inflammatory enzymes (iNOS). This creates an anaerobic environment that suppresses pathogenic bacteria like Enterobacteriaceae. Prioritize dietary fibers that promote butyrate production, such as resistant starches.

Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.

High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.

Obesity-induced inflammation involves a shift in adipose tissue macrophages from an anti-inflammatory M2 state to a pro-inflammatory M1 state, which secretes cytokines like TNF-α that block insulin signaling.

In obese individuals, fat tissue isn't just storage; it becomes an active immune organ. Fat cells attract immune cells that switch to a 'pro-inflammatory' mode (M1 macrophages), releasing chemicals like TNF-α that block insulin from working properly. Reducing this specific type of immune activation in fat tissue is key to improving metabolic health.

Inhibition of specific inflammatory signaling pathways (NF-κB and JNK) can disrupt the link between obesity and insulin resistance, suggesting these pathways are therapeutic targets.

Targeting the specific inflammatory signaling pathways (like JNK and NF-κB) that are overactive in obesity may help restore insulin sensitivity. While drugs targeting these are in development, current lifestyle interventions that reduce overall inflammation may indirectly modulate these pathways.

Current trends in the U.S. population project that by 2030, nearly 1 in 2 adults will have obesity (BMI ≥30) and nearly 1 in 4 will have severe obesity (BMI ≥35), with severe obesity becoming the most common BMI category among women, non-Hispanic black adults, and low-income adults.

This paper does not offer an individual intervention but highlights a massive public health trend. For an individual, the key takeaway is that the environment is becoming increasingly obesogenic, particularly for low-income and minority groups. Prevention efforts at the community and policy level are critical to counteracting these projected trends.

For a given waist circumference, a higher BMI is associated with lower mortality risk, likely due to greater protective subcutaneous fat storage in the lower body.

If you have a large waist, having a higher BMI might be less risky than having a low BMI with the same large waist. This is because lower-body fat may protect your organs from harmful visceral fat.

Greenspace exposure is associated with improved pregnancy outcomes, specifically a reduced risk of preterm birth and small size for gestational age.

For pregnant women, living in or frequently visiting areas with higher greenness is associated with a lower risk of preterm birth and having a baby that is small for gestational age. This suggests that environmental factors play a role in pregnancy health.

Caloric restriction (CR) is an effective intervention that impacts aging, age-related pathologies, and longevity in model organisms such as mice and rats.

While this paper confirms caloric restriction extends longevity in mice and rats, it does not provide specific human dosing protocols. For humans, this suggests that avoiding overconsumption and maintaining a healthy weight may support healthy aging, but specific restriction protocols should be discussed with a healthcare provider.

Epigenetic clocks, such as the DNAm PhenoAge and DunedinPoAm, can predict biological age, lifespan, and risk of chronic disease.

Epigenetic clocks are emerging tools to measure biological aging. While not yet standard clinical practice, they may eventually help individuals track the impact of lifestyle changes on their biological age.

Health-related stigma acts as a global barrier that impedes health-seeking behavior, engagement in care, and adherence to treatment across various conditions.

Health stigma is a major, documented barrier to getting care and sticking to treatment plans. It operates through social, cultural, and structural forces, not just individual psychology. To improve health outcomes, interventions must address these multi-level drivers rather than focusing solely on individual coping.

Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.

Metformin is the standard first-line medication for Type 2 Diabetes. It works by helping your liver produce less sugar and your body use insulin better. It typically lowers blood sugar by 1-2% without causing weight gain. If you have kidney issues, your doctor may adjust the dose or avoid it. Start with a low dose to minimize stomach upset.

Immune system activation (e.g., by microbial challenges) triggers an inflammatory response that increases sleep duration and intensity, serving as a homeostatic regulation of slow-wave sleep.

When you are sick, your body's increased sleep drive is a biological mechanism to help you recover. Listen to this signal and allow yourself to rest, as sleep actively supports your immune defense during infection.

Disease-associated inflammation is a primary etiologic driver of malnutrition, causing anorexia, increased resting energy expenditure, and muscle catabolism, distinct from simple starvation.

In sick patients, malnutrition isn't just about not eating enough; the body's inflammatory response actively breaks down muscle and increases energy needs. Treating the inflammation is as important as providing nutrition.

The global prevalence of sarcopenia varies significantly (10-27%) depending on the diagnostic classification and measurement instrument used, with no single standardized criterion currently established.

Because there is no single standard for diagnosing sarcopenia, prevalence rates you see in media or different clinics will vary widely (10-27%). If you are concerned about muscle loss, ask your provider which diagnostic criteria they are using (e.g., EWGSOP2) and which tool (DXA or BIA) they used, as this determines the result. Consistency in testing is more important than comparing your result to a global average.

The prevalence of severe sarcopenia ranges from 2% to 9% globally, with higher rates observed in European studies using EWGSOP criteria compared to Asian/Oceanic studies using other classifications.

Severe sarcopenia, which combines low muscle mass with poor physical performance (like slow gait speed), affects 2-9% of the population depending on how it is measured. It is a stronger predictor of mortality than sarcopenia alone, so early identification using standardized performance tests is critical.

Gut microbiota composition and activity influence host metabolism and immune function through mechanisms involving short-chain fatty acids (SCFAs) and bacterial endotoxins (LPS), but causal links are often confounded by environmental factors and relative abundance analysis errors.

Focus on dietary habits and lifestyle factors that support a diverse and active gut microbiome, such as consuming fermentable dietary fibers and maintaining healthy body weight. Be cautious of claims that specific single bacteria are universally 'good' or 'bad'; their effects depend on your diet and health status. Prioritize whole-food diets over isolated probiotic supplements for long-term gut health.

EPA and DHA stabilize atherosclerotic plaques by reducing macrophage infiltration and matrix metalloproteinase (MMP) expression, thereby lowering the risk of plaque rupture.

For patients with existing atherosclerosis, EPA and DHA supplementation may help stabilize plaques by reducing inflammation within the vessel wall. This is achieved by incorporating into the plaque and reducing macrophage presence, potentially lowering the risk of rupture.